Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma

Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …

AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks

Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 2 months

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma / 2 months

Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 3 hrs

DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 35 hrs